|MDACC Study No:||2010-0981 (clinicaltrials.gov NCT No: NCT01409161)|
|Title:||Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) with ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)|
|Principal Investigator:||Farhad Ravandi-Kashani|
|Treatment Agent:||Arsenic Trioxide; ATRA; Gemtuzamab Ozogamicin|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and gemtuzumab
ozogamicin (GO) can help to control APL. The safety of this drug combination
will also be studied.